These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21530217)

  • 1. Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?
    Bolin P; Gohh R; Kandaswamy R; Shihab FS; Wiland A; Akhlaghi F; Melancon K
    Transplant Rev (Orlando); 2011 Jul; 25(3):117-23. PubMed ID: 21530217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
    Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
    Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
    Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H
    Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
    Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
    Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
    Langone AJ; Chan L; Bolin P; Cooper M
    Transplantation; 2011 Feb; 91(4):470-8. PubMed ID: 21245794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
    Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
    Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
    Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
    J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
    Pietruck F; Budde K; Salvadori M; Sollinger H; Bourbigot B; Gentil MA; Oppenheimer F
    Clin Transplant; 2007; 21(1):117-25. PubMed ID: 17302600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.